南京市建邺区贤坤路江岛智立方 C 座 4 层 邮编:210019 电话: +86 25-83304480 传真: +86 25-83329335 释 义 本法律意见书中,除非文义另有所指,下列词语或简称具有如下含义: | 伟思医疗、公司、本 | 指 | 南京伟思医疗科技股份有限公司 | | --- | --- | --- | | 公司 | | | | 《激励计划》 | 뷰 | 《南京伟思医疗科技股份有限公司 2025年限制性股票 | | | | 激励计划》 | | 本激励计划、本次激 | 指 | 公司实施 2025年限制性股票激励计划的行为 | | 励计划 | | | | 预留授予 | 指 | 公司本次向激励对象授予预留限制性股票事项 | | 限制性股票 | 뷰 | 符合本次激励计划授予条件的激励对象,在满足相应归 属条件后分次获得并登记的公司股票 | | 激励对象 | 指 | 本次激励计划规定的符合授予限制性股票资格的人员 | | 授予日 | 損 | 公司向激励对象授予限制性股票的目期,授予目必须为 | | | | 交易日 | | 授予价格 | 指 | 公司向激励对象授予限制性股票时所确定的激励对象获 | ...

投资者可于 2025 年 11 月 6 日(星期四)至 11 月 12 日(星期三)17:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@vishee.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 南京伟思医疗科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 23 日发布《2025 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2025 年前三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日(星期四) 上午 11:00-12:00 举行 2025 第三季度业绩说明会，就投资者关心的问题进行交流。 证券代码：688580 证券简称：伟思医疗 公告编号：2025-039 南京伟思医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 11 月 13 日(星期四) 上午 11:00-12:00 四、投资者参加方式 （一）投资者 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-038 南京伟思医疗科技股份有限公司 第四届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《南 京伟思医疗科技股份有限公司 2025 年第三季度报告》。 （二）审议通过《关于向激励对象授予预留部分限制性股票的议案》 一、董事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第六次 会议于 2025 年 10 月 17 日以书面方式向全体董事发出。会议于 2025 年 10 月 22 日以现场结合通讯方式在公司会议室召开。 本次会议由董事长王志愚先生召集并主持，会议应到董事 7 人，实到董事 7 人，公司全体高级管理人员列席了会议。本次会议的召集、召开程序符合《中华 人民共和国公司法》等相关法律、行政法规、规范性文件及《南京伟思医疗科技 股份有限公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 ...

南京伟思医疗科技股份有限公司 2025 年第三季度报告 证券代码：688580 证券简称：伟思医疗 南京伟思医疗科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 注："本报告期"指本季度初至本季度末 3 个月期间，下同。 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 | 非经常性损益项目 | 本期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益，包括已计提 | - | -864.63 | | | 资产减值准备的冲销部分 ...

格隆汇10月22日丨伟思医疗(688580.SH)公布，公司前三季度实现营业收入3.26亿元，同比增长11.58%； 归属于上市公司股东的净利润1.02亿元，同比增长30.68%；归属于上市公司股东的扣除非经常性损益的 净利润9360万元，同比增长37.35%；基本每股收益1.07元。 ...

伟思医疗公告，第三季度营收为1.15亿元，同比增长14.87%；净利润为3282.4万元，同比增长14.99%。 前三季度营收为3.26亿元，同比增长11.58%；净利润为1.02亿元，同比增长30.68%。 ...

Core Viewpoint - Weisi Medical (688580.SH) reported a revenue of 326 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 11.58% [1] - The net profit attributable to shareholders reached 102 million yuan, marking a year-on-year increase of 30.68% [1] - The non-recurring net profit was 93.6 million yuan, showing a year-on-year growth of 37.35% [1] - The basic earnings per share stood at 1.07 yuan [1] Financial Performance - Revenue for the first three quarters: 326 million yuan, up 11.58% year-on-year [1] - Net profit attributable to shareholders: 102 million yuan, up 30.68% year-on-year [1] - Non-recurring net profit: 93.6 million yuan, up 37.35% year-on-year [1] - Basic earnings per share: 1.07 yuan [1]

Company Overview - Weisi Medical, established on January 10, 2001, is located in Nanjing, Jiangsu Province, and was listed on July 21, 2020. The company focuses on the research, development, production, and sales of rehabilitation medical devices, particularly in areas such as pelvic and postpartum rehabilitation, neurological rehabilitation, and mental rehabilitation [1]. Business Performance - As of October 17, Weisi Medical's stock price decreased by 5.08%, trading at 46.73 CNY per share, with a total market capitalization of 4.475 billion CNY. The trading volume was 70.9737 million CNY, and the turnover rate was 1.55% [1]. - The revenue composition of Weisi Medical includes: magnetic stimulation products (39.44%), consumables and accessories (19.42%), electrophysiological products (19.18%), laser radiofrequency products (10.26%), electrical stimulation products (8.42%), and others (3.28%) [1]. Fund Holdings - According to data, Beixin Ruifeng Fund holds a significant position in Weisi Medical through its health lifestyle theme flexible allocation fund (001056), which maintained 90,000 shares in the second quarter, accounting for 4.68% of the fund's net value, ranking as the seventh largest holding [2]. - The fund has a total scale of 90.1431 million CNY and has achieved a year-to-date return of 29.83%, ranking 2886 out of 8160 in its category [2]. Fund Management - The fund manager of Beixin Ruifeng's health lifestyle theme flexible allocation fund is Pang Wenjie, who has been in the position for 5 years and 140 days. The fund's total asset size is 18.4 million CNY, with the best return during his tenure being 44.46% and the worst being -40.05% [3].

Core Insights - The rehabilitation equipment industry in China is rapidly growing, with the market size expected to reach approximately 714.6 billion yuan in 2024, an increase of 98.9 billion yuan from 2023 [1][6] - The largest market share within the rehabilitation equipment sector is held by rehabilitation therapy devices at 15%, followed by rehabilitation training devices at 4%, and rehabilitation assessment devices at 1% [6] - The market is projected to grow further, reaching an estimated 815 billion yuan by 2025, driven by an aging population and increasing demand for rehabilitation services [1][6] Industry Definition and Classification - Rehabilitation medical devices are defined as equipment used for the prevention, assessment, treatment, training, or compensation of functional disabilities [3] - The main categories of rehabilitation medical devices include rehabilitation aids, rehabilitation therapy devices, rehabilitation training devices, rehabilitation assessment devices, and other rehabilitation equipment [3] Current Development Status - The rehabilitation equipment market in China is predominantly composed of domestic brands, which account for 97.9% of the market, while imported brands make up about 3% [6] - The industry has seen significant expansion in both market size and application areas due to rapid economic development [6] Industry Chain - The upstream of the rehabilitation equipment industry includes raw materials and software systems, while the midstream involves the manufacturing of rehabilitation devices [8] - The downstream applications primarily serve hospitals, community rehabilitation centers, nursing homes, and other medical institutions catering to populations with functional disabilities [8] Market Environment and Policies - The Chinese government has shown strong support for the rehabilitation equipment industry through various policies aimed at promoting its development, such as the "14th Five-Year" National Health Plan and guidelines for enhancing the welfare of the elderly [11] Competitive Landscape - Major companies in the rehabilitation medical device sector include Yuyue Medical, Kefu Medical, and Xiangyu Medical, with Yuyue Medical leading the market in terms of capital and revenue [12] - The industry exhibits a tiered competitive structure, with leading companies in the first tier and several others in subsequent tiers [12] Future Trends - The rehabilitation equipment industry is expected to experience significant growth opportunities, particularly in home settings, driven by an aging population and increasing chronic disease prevalence [13] - The industry is anticipated to evolve towards high-quality development, supported by technological advancements and favorable government policies [13]

Group 1 - The core viewpoint of the news is that Weisi Medical has shown significant stock performance, with a year-to-date increase of 86.61% and a recent trading volume indicating active investor interest [1][2] - As of October 9, Weisi Medical's stock price reached 50.59 CNY per share, with a market capitalization of 4.845 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 3.2557 million CNY, with large orders accounting for 19.27% of total purchases [1] Group 2 - Weisi Medical, established on January 10, 2001, specializes in the research, production, and sales of rehabilitation medical devices, focusing on areas such as pelvic floor rehabilitation and neurological recovery [2] - The company's revenue composition includes magnetic stimulation products (39.44%), consumables and accessories (19.42%), electrophysiological products (19.18%), laser radiofrequency products (10.26%), and electrical stimulation products (8.42%) [2] - For the first half of 2025, Weisi Medical reported a revenue of 210 million CNY, reflecting a year-on-year growth of 9.85%, and a net profit of 69.3242 million CNY, up 39.71% year-on-year [2]